Giuliana Pelicci

Giuliana Pelicci

Auto-generated profile, based on publicly available information

Giuliana Pelicci

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DODaniela Osti
Daniela Osti
MBMassimiliano Del Bene
Massimiliano Del Bene
GRGermana Rappa
Germana Rappa
MSMark Santos
Mark Santos
VMVittoria Matafora
Vittoria Matafora
GPGiuliana Pelicci
Giuliana Pelicci
Purpose: Glioblastoma (GBM) is the most common primary brain tumor. The identification of blood biomarkers reflecting the tumor status represents a major unmet need for optimal clinical management of patients with GBM. Their high number in body fluids, their stability, and the presence of many tumor-associated proteins and RNAs make extracellular vesicles potentially optimal biomarkers. Here, we investigated the potential role of plasma extracellular vesicles from patients with GBM for diagnosis and follow-up after treatment and as a prognostic tool. Experimental Design: Plasma from healthy controls (n = 33), patients with GBM (n = 43), and patients with different central nervous system malignancies (n = 25) were collected. Extracellular vesicles were isolated by ultracentrifugation and characterized in terms of morphology by transmission electron microscopy, concentration, and size by nanoparticle tracking analysis, and protein composition by mass spectrometry. An orthotopic mouse model of human GBM confirmed human plasma extracellular vesicle quantifications. Associations between plasma extracellular vesicle concentration and clinicopathologic features of patients with GBM were analyzed. All statistical tests were two-sided. Results: GBM releases heterogeneous extracellular vesicles detectable in plasma. Plasma extracellular vesicle concentration was higher in GBM compared with healthy controls (P < 0.001), brain metastases (P < 0.001), and extra-axial brain tumors (P < 0.001). After surgery, a significant drop in plasma extracellular vesicle concentration was measured (P < 0.001). Plasma extracellular vesicle concentration was also increased in GBM-bearing mice (P < 0.001). Proteomic profiling revealed a GBM-distinctive signature. Conclusions: Higher extracellular vesicle plasma levels may assist in GBM clinical diagnosis: their reduction after GBM resection, their rise at recurrence, and their protein cargo might provide indications about tumor, therapy response, and monitoring.

10 October 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MBMassimiliano Del Bene
Massimiliano Del Bene
DODaniela Osti
Daniela Osti
SFStefania Faletti
Stefania Faletti
GBGalina V Beznoussenko
Galina V Beznoussenko
FDFrancesco DiMeco
Francesco DiMeco
GPGiuliana Pelicci
Giuliana Pelicci
Glioblastoma (GBM) represents the most aggressive and lethal disease of the central nervous system. Diagnosis is delayed following the occurrence of symptoms, and treatment is based on standardized approaches that are unable to cope with its heterogeneity, mutability, and invasiveness. The follow-up of patients relies on burdensome schedules for magnetic resonance imaging (MRI). However, to personalize treatment, biomarkers and liquid biopsy still represent unmet clinical needs. Extracellular vesicles (EVs) may be the key to revolutionize the entire process of care for patients with GBM. EVs can be collected noninvasively (eg, blood) and impressively possess multilayered information, which is constituted by their concentration and molecular cargo. EV-based liquid biopsy may facilitate GBM diagnosis and enable the implementation of personalized treatment, resulting in customized care for each patient and for each analyzed time point of the disease, thereby tackling the distinctive heterogeneity and mutability of GBM that confounds effective treatment. Herein, we discuss the limitations of current GBM treatment options and the rationale behind the need for personalized care. We also review the evidence supporting GBM-associated EVs as a promising tool capable of fulfilling the still unmet clinical need for effective and timely personalized care of patients with GBM.

8 December 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
SFStefania Faletti
Stefania Faletti
DODaniela Osti
Daniela Osti
ECElena Ceccacci
Elena Ceccacci
CRCristina Richichi
Cristina Richichi
BCBrunella Costanza
Brunella Costanza
GPGiuliana Pelicci
Giuliana Pelicci
Inhibiting LSD1 reduces glioblastoma tumor-initiating cell survival by impeding their ability to handle the stress through the deregulation of ATF4.

24 May 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Roberta NoberiniRoberta Noberini
Roberta Noberini
CRCamilla Restellini
Camilla Restellini
ESEvelyn Oliva Savoia
Evelyn Oliva Savoia
FRFrancesco Raimondi
Francesco Raimondi
LGLavinia Ghiani
Lavinia Ghiani
Tiziana BonaldiTiziana Bonaldi
Tiziana Bonaldi
Aberrations in histone post-translational modifications (PTMs), as well as in the histone modifying enzymes (HMEs) that catalyze their deposition and removal, have been reported in many tumors and many epigenetic inhibitors are currently under investigation for cancer treatment. Therefore, profiling epigenetic features in cancer could have important implications for the discovery of both biomarkers for patient stratification and novel epigenetic targets. In this study, we employed mass spectrometry-based approaches to comprehensively profile histone H3 PTMs in a panel of normal and tumoral tissues for different cancer types, identifying various changes, some of which appear to be a consequence of the increased proliferation rate of tumors, while others are cell-cycle independent. Histone PTM changes found in tumors partially correlate with alterations of the gene expression profiles of HMEs obtained from publicly available data and are generally lost in culture conditions. Through this analysis, we identified tumor- and subtype-specific histone PTM changes, but also widespread changes in the levels of histone H3 K9me3 and K14ac marks. In particular, H3K14ac showed a cell-cycle independent decrease in all the seven tumor/tumor subtype models tested and could represent a novel epigenetic hallmark of cancer.

11 July 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
Roberta NoberiniRoberta Noberini
Roberta Noberini
Rémi LonguespéeRémi Longuespée
Rémi Longuespée
CRCristina Richichi
Cristina Richichi
GPGiancarlo Pruneri
Giancarlo Pruneri
Mark KriegsmannMark Kriegsmann
Mark Kriegsmann
Tiziana BonaldiTiziana Bonaldi
Tiziana Bonaldi
Aberrations in histone post-translational modifications (hPTMs) have been linked with various pathologies, including cancer, and could not only represent useful biomarkers but also suggest possible targetable epigenetic mechanisms. We have recently developed an approach, termed pathology tissue analysis of histones by mass spectrometry (PAT-H-MS), that allows performing a comprehensive and quantitative analysis of histone PTMs from formalin-fixed paraffin-embedded pathology samples. Despite its great potential, the application of this technique is limited by tissue heterogeneity. In this study, we further implemented the PAT-H-MS approach by coupling it with techniques aimed at reducing sample heterogeneity and selecting specific portions or cell populations within the samples, such as manual macrodissection and laser microdissection (LMD). When applied to the analysis of a small set of breast cancer samples, LMD-PAT-H-MS allowed detecting more marked changes between luminal A-like and triple negative patients as compared with the classical approach. These changes included not only the already known H3 K27me3 and K9me3 marks, but also H3 K36me1, which was found increased in triple negative samples and validated on a larger cohort of patients, and could represent a potential novel marker distinguishing breast cancer subtypes. These results show the feasibility of applying techniques to reduce sample heterogeneity, including laser microdissection, to the PAT-H-MS protocol, providing new tools in clinical epigenetics and opening new avenues for the comprehensive analysis of histone post-translational modifications in selected cell populations.

26 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CRCristina Richichi
Cristina Richichi
LFLorenzo Fornasari
Lorenzo Fornasari
GMGiorgio E. M. Melloni
Giorgio E. M. Melloni
PBPaola Brescia
Paola Brescia
MPMonica Patanè
Monica Patanè
GPGiuliana Pelicci
Giuliana Pelicci
Brain metastases (BMs) are the most common malignancy of the central nervous system. Recently it has been demonstrated that plasminogen activator inhibitor serpins promote brain metastatic colonization, suggesting that mutations in serpins or other members of the coagulation cascade can provide critical advantages during BM formation. We performed whole-exome sequencing on matched samples of breast cancer and BMs and found mutations in the coagulation pathway genes in 5 out of 10 BM samples. We then investigated the mutational status of 33 genes belonging to the coagulation cascade in a panel of 29 BMs and we identified 56 Single Nucleotide Variants (SNVs). The frequency of gene mutations of the pathway was significantly higher in BMs than in primary tumours, and SERPINI1 was the most frequently mutated gene in BMs. These findings provide direction in the development of new strategies for the treatment of BMs.